Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05163301 · ClinicalTrials.gov registry record · NA

Alcohol Research in HIV: Relapse Prevention

A NA study of HIV and Alcohol Use Disorder, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT05163301: Recruiting NA study of HIV and Alcohol Use Disorder, sponsored by Johns Hopkins University.

NCT05163301 is a NA study of HIV and Alcohol Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 150 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05163301, a NA study of HIV and Alcohol Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

3-arm type 1 pilot implementation-efficacy trial for people with alcohol use disorders to examine the preliminary effectiveness and feasibility of an adapted 2-session, computerized and person delivered relapse prevention intervention.

Primary Outcome

Time to return to any alcohol use or any at risk alcohol use after intervention.

Conditions Studied

Interventions

  • BEHAVIORAL Relapse Prevention Intervention

Study Locations (1)

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-03-27
Est. Completion 2027-05-31
Phase NA
Johns Hopkins University

1,448 total trials

What NCT05163301 shows while recruiting

NCT05163301 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (66% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Relapse Prevention Intervention is the first listed.

NCT05163301 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05163301 about?

NCT05163301 is a clinical study titled "Alcohol Research in HIV: Relapse Prevention". 3-arm type 1 pilot implementation-efficacy trial for people with alcohol use disorders to examine the preliminary effectiveness and feasibility of an adapted 2-session, computerized and person delivered relapse prevention intervention.

What is the current status of trial NCT05163301?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-03-27. Estimated completion is 2027-05-31.

What conditions does trial NCT05163301 study?

This clinical trial studies the following conditions: HIV, Alcohol Use Disorder.

What interventions are being tested in trial NCT05163301?

The interventions under investigation include: Relapse Prevention Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05163301?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05163301 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05163301's enrollment target sits among peer trials

150 130th of 303 higher than 172 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05163301, the US trial registry maintained by the National Library of Medicine. NCT05163301 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.